Hemolytic uremic syndrome: Epidemiology, pathophysiology, and therapy. Proceedings of the American Society of Pediatric Nephrology Educational Symposium, May 2000, Boston, Massachusetts, USA

Pediatric Nephrology

Volumn 17, Issue 4, 2002, Pages 293-298

  Andreoli, Sharon P ^a   Trachtman, Howard ^b   Acheson, David W K ^c   Siegler, Richard L ^e   Obrig, Tom G ^d  

^a RILEY HOSPITAL FOR CHILDREN   (United States)

^b LONG ISLAND JEWISH MEDICAL CENTER   (United States)

^c TUFTS MEDICAL CENTER   (United States)

^d UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^e NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; ANTIINFECTIVE AGENT; ANTITHROMBOCYTIC AGENT; BACTERIUM LIPOPOLYSACCHARIDE; CELL RECEPTOR; CHEMOKINE; COTRIMOXAZOLE; CYTOKINE; DIPYRIDAMOLE; DNA; FIBRINOLYTIC AGENT; FUROSEMIDE; GLOBOTRIAOSYLCERAMIDE; GLYCOLIPID; HEPARIN; IMMUNOGLOBULIN; MONOCLONAL ANTIBODY; PROSTACYCLIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RICIN; SHIGA TOXIN; STEROID; STREPTOKINASE; TOXIN ANTIBODY; TUMOR NECROSIS FACTOR; UNINDEXED DRUG; VASCULOTROPIN; VON WILLEBRAND FACTOR;

ANTIBIOTIC THERAPY; BACTERIAL SUPERINFECTION; BACTERIAL VIRULENCE; BACTERIUM ADHERENCE; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATION; CELL DAMAGE; CHILD; CONFERENCE PAPER; DIARRHEA; DISEASE MODEL; DOG; DRUG MEGADOSE; ENTEROBACTER INFECTION; ESCHERICHIA COLI O157; FECES ANALYSIS; GERMFREE ANIMAL; HEMOLYTIC UREMIC SYNDROME; HOST PATHOGEN INTERACTION; HUMAN; MOUSE; NONHUMAN; PATHOPHYSIOLOGY; PLASMA TRANSFUSION; PLASMAPHERESIS; PREVALENCE; PRIMATE; PRIORITY JOURNAL; RABBIT; RAT; SEROTYPE; SWINE;

ANIMALS; BACTERIAL INFECTIONS; DIARRHEA; DISEASE MODELS, ANIMAL; DISEASE OUTBREAKS; HEMOLYTIC-UREMIC SYNDROME; HUMANS; SHIGA TOXINS; UNITED STATES;

EID: 0036947232     PISSN: 0931041X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00467-001-0783-0     Document Type: Conference Paper

References (44)

1. Riley LW, Remis RS, Helgerson SD, McGee HB, Wells JG, Davis BR, Hebert RJ, Olcott ES, Johnson LM, Hargrett NT, Blake PA, Cohen ML (1983) Hemorrhagic colitis associated with a rare Escherichia coli serotype. N Engl J Med 308:681-685
2. Paton JC, Paton AW (1998) Pathogenesis and diagnosis of Shiga toxin-producing Escherichia coli infections. Clin Microbiol Rev 11:450-479
3. Karmali MA, Petric M, Lim C, Fleming PC, Arbus GS, Lior H (1985) The association between idiopathic hemolytic uremic syndrome and infection by verotoxin-producing Escherichia coli. J Infect Dis 151:775-782
4. Acheson DWK, Keusch GT (1999) The family of Shiga toxins. In: Alouf SE, Freer JH (eds) The comprehensive source-book of bacterial protein toxins. Academic Press, London, pp 229-242
5. Acheson DWK, Keusch GT (1996) Which Shiga toxin-producing types of E. coli are important? ASM News 62:302-306
6. Bergmire-Sweat D, Marengo L, Pendergrass P, et al (2000) Escherichia coli O111:H8 outbreak among teenage campers - Texas. MMWR 49:321-324
7. Paton AW, Ratcliff RM, Doyle RM, Seymour-Murray J, Davos D, Lanser JA, Paton JC (1996) Molecular microbiological investigation of an outbreak of hemolytic-uremic syndrome caused by dry fermented sausage contaminated with Shiga-like toxin-producing Escherichia coli. J Clin Microbiol 34:1622-1627
8. Boyce TG, Pemberton AG, Wells JG, Griffin PM (1995) Screening for Escherichia coli O157:H7 - a nationwide survey of clinical laboratories. J Clin Microbiol 33:3275-3277
9. Park CH, Gates KM, Vandel NM, Hixon DL (1996) Isolation of Shiga-like toxin producing Escherichia coli (O157 and non-O157) in a community hospital. Diagn Microbiol Infect Dis 26:69-72
10. Kehl KS, Havens P, Behnke CE, Acheson DWK (1997) Evaluation of the Premier EHEC assay for detection of Shiga toxin-producing Escherichia coli. J Clin Microbiol 35:2051-2054
11. Fey PD, Wicket RS, Rupp ME, Safranek TJ, Hinrichs SH (2000) Prevalence of non-O157:H7 Shiga toxin-producing Escherichia coli in diarrheal stool samples in Nebraska. Emerg Infect Dis 6:530-533
12. Wong CS, Jelacic S, Habeeb RL, Watkins SL, Tarr PI (2000) The risk of the hemolytic uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections. N Engl J Med 342:1930-1936
13. Zhang X, McDaniel AD, Wolf LE, Keusch GT, Waldor DWK (2000) Quinolone antibiotic induces Shiga toxin encoding bacteriophages, toxin production and death in mice. J Infect Dis 181:664-670
14. Barrett TJ, Potter ME, Wachsmuth IK (1989) Bacterial endotoxin both enhances and inhibits the toxicity of Shiga-like toxin II in rabbits and mice. Infect Immun 57:3434-3437
15. Taylor CM, Williams JM, Lote CJ, Howie AJ, Thewles A, Wood JA, Milford DV, Raafat F, Chant I, Rose RE (1999) A laboratory model of toxin-induced hemolytic uremic syndrome. Kidney Int 55:1367-1374
16. Richardson SE, Rotman TA, Jay V, Smith CR, Becker LE, Olivieri NF, Karmali MA (1992) Experimental verocytotoxemia in rabbits. Infect Immun 60:4154-4167
17. Baker DR, Moxley RA, Francis DH (1997) Variation in virulence in the gnotobiotic pig model of 0157:H7 Escherichia coli strains of bovine and human origin. In: Paul et al. (eds) Mechanisms in the pathogenesis of enteric diseases. Plenum Press, New York, pp 53-58
18. Hertzke DM, Cowan LA, Schoning P, Fenwick BW (1995) Glomerular ultrastructural lesions of idiopathic cutaneous and renal glomerular vasculopathy of greyhounds. Vet Pathol 32:451-459
19. Taylor FB Jr, Tesh VL, deBault L, Li A, Chang AC, Kosanke SC, Pysher TJ, Siegler RL (1999) Characterization of the baboon responses to Shiga-like toxin: descriptive study of a new primate model of toxic responses to Stx-1. Am J Pathol 154:1285-1299
20. Andreoli SP (1999) The pathophysiology of the hemolytic uremic syndrome. Curr Opin Nephrol Hypertens 8:459-464
21. O'Brien AD, Tesh VL, Donohue-Rolfe A, Jackson MP, Olsnes S, Sandvig K, Lindberg AA, Keusch GT (1992) Shiga toxin: biochemistry, genetics, mode of action, and role in pathogenesis. Curr Top Microbiol Immunol 180:65-94
22. Pickering LK, Obrig TG, Stapleton FB (1994) Hemolytic uremic syndrome and enterohemorrhagic Escherichia coli. Pediatr Infect Dis J 13:459-476
23. Hughes AK, Stricklett PK, Kohan DE (1998) Shiga toxin-1 regulation of cytokine production by human proximal tubule cells. Kidney Int 54:1093-1106
24. Obrig TG, Louise CB, Lingwood CA, Boyd B, Barley-Maloney L, Daniel TO (1993). Endothelial heterogeneity in Shiga toxin receptors and responses. J Biol Chem 268:15484-15488
25. Setten PA van, Monnens LA, Verstraten RG, Heuvel LP van den, Hinsbergh VW van (1996) Effects of verocytotoxin-1 on nonadherent human monocytes: binding characteristics, protein synthesis, and induction of cytokine release. Blood 88:174-183
26. Louise CB, Tran MC, Obrig TG (1997) Sensitization of human umbilical vein endothelial cells to Shiga toxin: involvement of protein kinase C and NF-kappaB. Infect Immun 65:3337-3344
27. Morigi M, Micheletti G, Figliuzzi M, Imberti B, Karmali MA, Remuzzi A, Remuzzi G, Zoja C (1995) Verotoxin-1 promotes leukocyte adhesion to cultured endothelial cells under physiologic flow conditions. Blood 86:4553-4558
28. Galbusera M, Noris M, Rossi C, Orisio S, Caprioli J, Ruggeri ZM, Amadei B, Ruggenenti P, Vasile B, Casari G, Remuzzi G (1999) Increased fragmentation of von Willebrand factor, due to abnormal cleavage of the subunit, parallels disease activity in recurrent hemolytic uremic syndrome and thrombotic thrombocytopenic purpura and discloses predisposition in families. The Italian Registry of Familial and Recurrent HUS/TTP. Blood 94:610-620
29. Gerritsen HE, Turecek PL, Schwarz HP, Lammle B, Furlan M (1999) Assay of von Willebrand factor (vWF)-cleaving protease based on decreased collagen binding affinity of degraded vWF: a tool for the diagnosis of thrombotic thrombocytopenic purpura. Thromb Haemost 82:1386-1389
30. Karpman D, Papadopoulou D, Nilsson K, Sjogren AC, Mikaelsson C, Lethagen S (2001) Platelet activation by Shiga toxin and circulatory factors as a pathogenic mechanisms in the hemolytic uremic syndrome. Blood 97:3100-3108
31. Trachtman H, Christen, E (1999) Pathogenesis, treatment, and therapeutic trials in hemolytic uremic syndrome. Curr Opin Pediatr 11:162-168
32. Kaplan BS, Meyers KE, Schulman SL (1998) The pathogenesis and treatment of hemolytic uremic syndrome. J Am Soc Nephrol 9:1126-1133
33. Brandt JR, Fouser LS, Watkins SL, Zelikovic I, Tarr PI, Nazar-Stewart V, Avner ED (1994) Escherichia coli O157:H7-associated hemolytic-uremic syndrome after ingestion of contaminated hamburgers. J Pediatr 125:519-526
34. Van Damme-Lombaerts R, Proesmans W, Van Damme B, Eeckels R, Binda ki Muaka P, Mercieca V, Vlietinck R, Vermylen J (1988) Heparin plus dipyridamole in childhood hemolytic-uremic syndrome: a prospective, randomized study. J Pediatr 113:913-918
35. Robson WLM, Fick GH, Jadavji T, Leung AKC (1991) The use of intravenous gammaglobulin in the treatment of typical hemolytic uremic syndrome. Pediatr Nephrol 5:289-292
36. Perez N, Spizziri F, Rahman R, Suarez A, Larrubia C, Lasarte P (1998) Steroids in the hemolytic uremic syndrome. Pediatr Nephrol 12:101-104
37. O'Regan S, Chesney RW, Mongeau JG, Robitaille P (1980) Aspirin and dipyridamole therapy in the hemolytic-uremic syndrome. J Pediatr 97:473-476
38. Rousseau E, Blais N, O'Regan S (1990) Decreased necessity for dialysis with loop diuretic therapy in hemolytic uremic syndrome. Clin Nephrol 34:22-25
39. Gianviti A, Perna A, Caringella A, Edefonti A, Penza R, Remuzzi G, Rizzoni G (1993) Plasma exchange in children with hemolytic-uremic syndrome at risk of poor outcome. Am J Kidney Dis 22:264-266
40. Yoshioka K, Yagi K, Moriguchi N (1996) Clinical features and treatment of children with hemolytic uremic syndrome caused by enterohemorrhagic Escherichia coli O157:H7 infection: experience of an outbreak in Sakai city, 1996. Pediatr Int 41:223-227
41. Donohue-Rolfe A, Kondova J, Mukherjee J, Chios K, Hutto D, Tzipori S (1999) Antibody-based protection of gnotobiotic piglets infected with Escherichia coli O157:H7 against systemic complications associated with Shiga toxin 2. Infect. Immun 67:3645-3648
42. Diez-Gonzalez F, Callaway TR, Kizoulis MG, Russell JB (1998) Grain feeding and the dissemination of acid-resistant Escherichia coli from cattle. Science 28:1666-1668
43. Konadu EY, Parke JC Jr, Tran HT, Bryla DA, Robbins JB, Szu SC (1998) Investigational vaccine for Escherichia coli O157: phase 1 study of O157 O-specific polysaccharide-Pseudomonas aeruginosa exoprotein A conjugates in adults. J Infect Dis 177:383-387
44. Ikeda K, Ida O, Kimoto K, Takatorige T, Nakanishi N, Tatara K (1999) Effect of early fosfomycin treatment on prevention of hemolytic uremic syndrome accompanying Escherichia coli infection. Clin Nephrol 52:357-362